Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
← catalyst calendarNCT05518578 · readout in 498 d
Sponsored by Supernus Pharmaceuticals, Inc. (industry) · SUPN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
10
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-07 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epilepsy
- Seizures, Epileptic
Intervention
- Drug: SPN-817 — also filed as (-)-Huperzine A extended-release
Primary outcome
what the primary-completion date above is the date OFEffects of SPN-817 on safety and tolerability
measured 72 weeks
Permalink · SUPN's whole pipeline · Catalyst calendar · Every registered study · What changed